Qiuji Wu
Biographic Data
| ID | 10010422 |
|---|---|
| NAME | Qiuji Wu |
| GIVEN NAMES | Qiuji |
| FAMILY NAME | Wu |
| SIGNATURE | WU Q |
| AFFILIATIONS | Sichuan University |
| ORCID | 0000-0001-9205-4193 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2025 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Nivolumab plus ipilimumab versus lenvatinib or sorafenib for US and Chinese patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis
Background: The CheckMate 9DW trial showed that nivolumab plus ipilimumab (NIVO + IPI) improves overall survival over lenvatinib or sorafenib (LEN/SOR) in patients with unresectable hepatocellular carcinoma (uHCC). We evaluated the cost-effectiveness of NIVO + IPI versus LEN/SOR from payer perspectives in the United States (US) and China, explicitly aiming to inform reimbursement and price-negotiation decisions in each setting. Methods: Based on …
Cost-effectiveness of atezolizumab versus chemotherapy in patients with non-small-cell lung cancer ineligible for platinum-based doublet chemotherapy
Background: Atezolizumab has recently demonstrated improved prognosis in patients with advanced or metastatic non-small-cell lung cancer (NSCLC) who are not eligible for treatment with a platinum-containing regimen, as observed in a randomized phase 3 clinical trial. This study aims to evaluate the cost-effectiveness of atezolizumab for the treatment of NSCLC from the perspective of payers in both developed and developing countries. Materials and…
No prominent works on this page.
Cost-effectiveness of atezolizumab versus chemotherapy in patients with non-small-cell lung cancer ineligible for platinum-based doublet chemotherapy
Background: Atezolizumab has recently demonstrated improved prognosis in patients with advanced or metastatic non-small-cell lung cancer (NSCLC) who are not eligible for treatment with a platinum-containing regimen, as observed in a randomized phase 3 clinical trial. This study aims to evaluate the cost-effectiveness of atezolizumab for the treatment of NSCLC from the perspective of payers in both developed and developing countries. Materials and…
Nivolumab plus ipilimumab versus lenvatinib or sorafenib for US and Chinese patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis
Background: The CheckMate 9DW trial showed that nivolumab plus ipilimumab (NIVO + IPI) improves overall survival over lenvatinib or sorafenib (LEN/SOR) in patients with unresectable hepatocellular carcinoma (uHCC). We evaluated the cost-effectiveness of NIVO + IPI versus LEN/SOR from payer perspectives in the United States (US) and China, explicitly aiming to inform reimbursement and price-negotiation decisions in each setting. Methods: Based on …
Cancer Immunotherapy and Biomarkers (2 works) · Economic and Financial Impacts of Cancer (2 works) · Atezolizumab (1 works) · Cancer (1 works) · Chemotherapy (1 works) · Clinical trial (1 works) · Health Systems, Economic Evaluations, Quality of Life (1 works) · Hepatocellular carcinoma (1 works) · Hepatocellular Carcinoma Treatment and Prognosis (1 works) · Immunotherapy (1 works)